Patents by Inventor Andrew Luber

Andrew Luber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MK2 INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME
    Publication number: 20190022176
    Abstract: The described invention provides pharmaceutical compositions, systems and methods for treating a solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
    Type: Application
    Filed: May 11, 2018
    Publication date: January 24, 2019
    Inventors: Cynthia Lander, Colleen Brophy, Caryn Peterson, Andrew Luber
  • Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
    Patent number: 9999655
    Abstract: Pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells are described. In some aspects, administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 19, 2018
    Assignee: Moerae Matrix, Inc.
    Inventors: Cynthia Lander, Colleen Brophy, Caryn Peterson, Andrew Luber
  • USE OF MKS INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME
    Publication number: 20160263187
    Abstract: The described invention provides pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 15, 2016
    Inventors: Cynthia Lander, Colleen Brophy, Caryn Peterson, Andrew Luber